Next Article in Journal
Thermodynamic Aspects and Reprogramming Cellular Energy Metabolism during the Fibrosis Process
Next Article in Special Issue
Physiological and Pathological Roles of CaMKII-PP1 Signaling in the Brain
Previous Article in Journal
Cortisol Awakening Response, Internalizing Symptoms, and Life Satisfaction in Emerging Adults
Previous Article in Special Issue
Site-Directed Mutagenesis of the Fibronectin Domains in Insulin Receptor-Related Receptor
Article Menu
Issue 12 (December) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2017, 18(12), 2543;

Protein Kinase Targets in Breast Cancer

Biochemistry Department, Hospital Costa del Sol, REDISSEC, Carretera de Cádiz km, 187, 29600 Marbella, Málaga, Spain
Biochemistry Department, Facultad de Medicina de la Universidad de Málaga, Bulevar Louis Pasteur 32, 29010 Málaga, Spain
Author to whom correspondence should be addressed.
Received: 29 September 2017 / Revised: 20 November 2017 / Accepted: 22 November 2017 / Published: 27 November 2017
(This article belongs to the Special Issue Kinase Signal Transduction 2017)
Full-Text   |   PDF [9488 KB, uploaded 28 November 2017]   |  


With 1.67 million new cases and 522,000 deaths in the year 2012, breast cancer is the most common type of diagnosed malignancy and the second leading cause of cancer death in women around the world. Despite the success of screening programs and the development of adjuvant therapies, a significant percentage of breast cancer patients will suffer a metastatic disease that, to this day, remains incurable and justifies the research of new therapies to improve their life expectancy. Among the new therapies that have been developed in recent years, the emergence of targeted therapies has been a milestone in the fight against cancer. Over the past decade, many studies have shown a causal role of protein kinase dysregulations or mutations in different human diseases, including cancer. Along these lines, cancer research has demonstrated a key role of many protein kinases during human tumorigenesis and cancer progression, turning these molecules into valid candidates for new targeted therapies. The subsequent discovery and introduction in 2001 of the kinase inhibitor imatinib, as a targeted treatment for chronic myelogenous leukemia, revolutionized cancer genetic pathways research, and lead to the development of multiple small-molecule kinase inhibitors against various malignancies, including breast cancer. In this review, we analyze studies published to date about novel small-molecule kinase inhibitors and evaluate if they would be useful to develop new treatment strategies for breast cancer patients. View Full-Text
Keywords: breast cancer; kinases; phosphatases; target breast cancer; kinases; phosphatases; target

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

García-Aranda, M.; Redondo, M. Protein Kinase Targets in Breast Cancer. Int. J. Mol. Sci. 2017, 18, 2543.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top